136 results on '"Ngo, Leock"'
Search Results
2. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (aged 4 to
3. Sustained seizure freedom with adjunctive perampanel in patients with convulsive seizures: Post hoc analysis of open-label extension studies 307 and 332
4. Time to prerandomization seizure count design sufficiently assessed the safety and tolerability of perampanel for the treatment of primary generalized tonic–clonic seizures.
5. A post-approval observational study to evaluate the safety and tolerability of perampanel as an add-on therapy in adolescent, adult, and elderly patients with epilepsy
6. Health-related quality of life in pediatric patients with partial onset seizures or primary generalized tonic-clonic seizures receiving adjunctive perampanel
7. Adjunctive perampanel and myoclonic and absence seizures: Post hoc analysis of data from study 332 in patients with idiopathic generalized epilepsy
8. Perampanel for treatment of focal and generalized epilepsy in everyday clinical practice: Evidence from permit extension
9. Adjunctive perampanel for myoclonic and absence seizures: A post hoc pooled analysis of seizure-free days in studies 332, 311, and 232
10. Efficacy and safety of perampanel in a randomized, placebo-controlled trial with an open-label extension in patients with seizures associated with Lennox-Gastaut syndrome (LGS)
11. Intravenous perampanel as an alternative to the oral formulations in Japanese patients with epilepsy
12. Perampanel for Treatment of Focal and Generalized Epilepsy in Everyday Clinical Practice: Evidence from PERMIT and PROVE (P11-1.008)
13. Time to exceed pre‐randomization monthly seizure count for perampanel in participants with primary generalized tonic–clonic seizures: A potential clinical end point
14. 069 Real-world evidence on the safety and efficacy of adjunctive perampanel across different geographical regions
15. 070 Real-world experience of perampanel monotherapy in epilepsy patients with focal-onset and generalised-onset seizures
16. 2234 Perampanel for the treatment of paediatric patients in clinical practice by age category
17. 2262 Study 238: interim safety of adjunctive perampanel in patients (aged ≥1 to <24 months) with epilepsy: treatment-emergent adverse events (TEAEs) of interest and serious TEAEs
18. 2248 Perampanel monotherapy for focal-onset seizures (FOS): post hoc analysis of treatment-emergent adverse events (TEAEs) by treatment period during FREEDOM study 342
19. 156 Long-term effects of perampanel on cognition, growth/development in paediatric patients with epilepsy study 311
20. 160 Long-term cognitive effects of perampanel in paediatric patients with epilepsy by responder status and dose
21. 015 Long-term (1-year) seizure freedom with adjunctive perampanel in paediatric patients with epilepsy: study 311
22. 016 Long-term efficacy and safety of perampanel in elderly patients from phase III open-label extension studies
23. 017 PROVE study 506: perampanel in real-world clinical care of patients based on seizure type
24. 014 Efficacy and safety of perampanel for myoclonic and absence seizures: studies 332, 311 and 232
25. Intravenous Perampanel as an Interchangeable Alternative to Oral Perampanel: A Randomized, Crossover, Phase I Pharmacokinetic and Safety Study
26. Real-World Experience of Perampanel Monotherapy in Epilepsy Patients with Focal-Onset and Generalized-Onset Seizures (P15-8.002)
27. Real-world experience of perampanel monotherapy in epilepsy patients with focal-onset and generalised-onset seizures
28. Experience of perampanel monotherapy beyond initial titration to achieve seizure freedom in patients with focal‐onset seizures with newly diagnosed or currently untreated recurrent epilepsy: A post hoc analysis of the open‐label Study 342 (FREEDOM)
29. 22 Sustained Seizure Freedom With Perampanel as Adjunctive Therapy or Monotherapy in Open-Label Extension (OLEx) Studies 307, 332, and 342
30. Long-Term (1-Year) Evaluation of Adjunctive Perampanel on Mental Health in Pediatric Patients (Aged 4–<12 Years) with Partial-Onset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) in Study 311 (1304)
31. Perampanel Monotherapy Beyond Initial Titration to Achieve Seizure Freedom in Patients With Partial-Onset Seizures (POS), With/Without Secondarily Generalized Seizures (SGS): Post Hoc Analysis of Phase III Study 342 (FREEDOM) (1969)
32. Effectiveness and Tolerability of Perampanel in Epilepsy Patients Treated in Routine Clinical Practice: a Global Pooled Analysis Study (1640)
33. Efficacy and Safety of Adjunctive Perampanel for Myoclonic and Absence Seizures: Post Hoc Pooled Analysis of Adult, Adolescent, and Pediatric Patients in Studies 332, 311, and 232 (1331)
34. Perampanel Monotherapy in Epilepsy Patients with Focal and Generalized Seizures: Real-World Experience (1641)
35. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy
36. Experience of perampanel monotherapy beyond initial titration to achieve seizure freedom in patients with focal‐onset seizures with newly diagnosed or currently untreated recurrent epilepsy: A post hoc analysis of the open‐label Study 342 (FREEDOM)
37. Structure-inhibitory profiles of nucleosides for the human intestinal N1 and N2 Na+-nucleoside transporters
38. Human intestinal es nucleoside transporter: molecular characterization and nucleoside inhibitory profiles
39. Efficacy and Safety of Adjunctive Perampanel in South Korean Patients with Partial-Onset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures (PGTCS): Post Hoc Analysis of Phase II and III Double-Blind and Open-Label Extension (OLEx) Studies (1325)
40. Efficacy and Safety of Adjunctive Perampanel 4 mg/day in Pediatric Patients (Aged 4 to <12 Years) with Partial-Onset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) in Study 311 (4134)
41. Effect of Concomitant Enzyme-Inducing Antiepileptic Drugs (EIAEDs) on the Efficacy and Safety of Adjunctive Perampanel 4 mg/day in Patients Aged ≥12 Years with Partial-Onset Seizures in Asia-Pacific Study 335 (4246)
42. Post Hoc Univariate and Multivariate Analyses to Identify Clinical Factors Associated with a 50% or 75% Response in a Phase III Trial of Adjunctive Perampanel in Patients with Primary Generalized Tonic-Clonic Seizures (PGTCS) (1834)
43. Long-term Safety and Efficacy of Adjunctive Perampanel in Pediatric Patients (Aged 4 to <12 years) with Partial-Onset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) in Study 311 (413)
44. Open‐label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic‐clonic seizures
45. Intestinal Absorption of Ribavirin Is Preferentially Mediated by the Na+-Nucleoside Purine (Nl) Transporter
46. Effect of Concomitant Enzyme-Inducing Antiepileptic Drugs (EIAEDs) on the Safety and Efficacy of Adjunctive Perampanel in Patients Aged 4 to <12 years with Partial-Onset Seizures (POS): Final Results from the 311 Core Study (P3.5-007)
47. Safety and Efficacy of Adjunctive Perampanel in Younger (aged 4 to <7 years) and Older (7 to <12 years) Pediatric Patients with Partial-Onset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures (PGTCS): Final Results from the 311 Core Study (P1.5-021)
48. Phase II, Open-Label Pharmacokinetic (PK) Study of Perampanel Oral Suspension as Adjunctive Therapy in Pediatric Patients (Aged ≥1 to <24 months) with Epilepsy: Study 238 Design and Preliminary Safety Data (P3.5-017)
49. Safety and Efficacy of Adjunctive Perampanel in Pediatric Patients (Aged 4 to <12 Years) with Partial-Onset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures (PGTCS): Final Results from the 311 Core Study (P3.5-001)
50. Pharmacokinetic (PK) Assessment of Perampanel Intravenous (IV) Formulation as a Bioequivalent Alternative to Oral Tablet Administration (P1.5-029)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.